Target intelligence / Profile preview

T cell receptor beta variable 7-8 (TRBV7-8)

Target
TRBV7-8
Molecular classification
Receptor (T cell receptor component), Immunoglobulin superfamily (IgSF) member, Cell surface protein
01

Overview

T cell receptor beta variable 7-8 (TRBV7-8) encodes the variable region of the T cell receptor beta chain, which is critical for peptide-MHC complex recognition and the initiation of T cell–mediated immune responses[3][5][6]. The TCR is a membrane-anchored heterodimeric protein composed in most human T cells of α and β chains, each formed by unique V(D)J recombination events. The TRBV7-8 segment provides part of the diversity enabling individual TCRs to specifically recognize diverse antigens. The β chain variable region forms, together with its α counterpart, the antigen binding site that dictates T cell specificity and determines immune repertoire diversity[3][5]. Variability in TRBV gene usage, including TRBV7-8, has functional implications for immune surveillance and is associated with various immune pathologies, but TRBV7-8 itself is not typically a therapeutic target[8].

Other names
TRBV7-8TVB78TCRBV7S8Variable region of T cell receptor beta chain 7-8
02

Mechanism of action

No approved drugs with a mechanism specific to TRBV7-8. The overall TCR complex functions via antigen-specific activation and signal transduction through CD3 and downstream kinases.

03

Biological functions

Antigen recognition (as part of the αβ T cell receptor)Immune response activationT cell signaling and developmentAdaptive immunity, including interaction with antigens presented by MHC molecules
04

Disease associations

Autoimmune disease (polymorphisms in TRBV genes have been linked to autoimmune disease susceptibility and immune-related adverse events)Cancer (alterations in TCR repertoires, including TRBV segments, are studied in immuno-oncology)Infection (part of pathogen recognition by adaptive immunity)Other immune-related diseases
05

Safety considerations

No unique safety concerns known for TRBV7-8 itself.Off-target immune activation (associated with general TCR-targeted therapies)Cytokine release syndrome (associated with general TCR-targeted therapies)Autoimmunity (associated with general TCR-targeted therapies)
06

Biomarkers

TCR sequencing (including TRBV segment usage) for immunotherapy monitoringTCR sequencing for immune response assessment

Beyond the preview

Go deeper on T cell receptor beta variable 7-8 (TRBV7-8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor beta variable 7-8 (TRBV7-8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call